Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that using PRP injections in skin flap reconstructions and combining acellular dermal matrix with split-thickness skin grafts improved healing and reduced complications in the surgical treatment of hidradenitis suppurativa.

This review discusses the potential of platelet-rich plasma in regenerative medicine and aging-related diseases but notes that clinical efficacy remains unclear due to varying study results and preparation inconsistencies.

This review discusses the potential efficacy and applications of platelet-rich plasma in dermatology, highlighting its use in various skin conditions but reporting no new clinical results; the authors call for standardization of preparation and treatment methods.

This commentary reviews clinical trials on platelet-rich plasma treatments for androgenetic alopecia and emphasizes the need for standardized preparation methods and concentrations; it reports no new clinical results.

A new gene mutation may allow some piebaldism patients to regain skin color in white patches.

This study found that hair depigmentation in mice and humans can be a dynamic indicator of KIT inhibition by the drug SU11248, correlating with treatment periods.

MultiKano accurately identifies cell types in complex data better than existing methods.

This study will explore skin and hair characteristics of pregnant women and their newborns, examining the relationships between these factors and the newborns' skin maturation over time.

This study concluded that the KNPs@M/G microneedle system offers a promising strategy for treating radiation-induced skin injury by promoting antioxidative, anti-inflammatory, and regenerative effects.

This article introduces signatureSearch, a software package designed for gene expression signature searching and functional enrichment analysis, but reports no new clinical results.

This study reviews the role of the KIT ligand and receptor pathway in managing melanocyte and mast cell-related skin diseases, examining how its regulation can lead to potential therapies for conditions like vitiligo, melanoma, and mastocytosis. Results are not reported.

This study reports that a clinical prognostic model based on immune-related genes improved survival prediction for patients with clear cell renal cell carcinoma, also identifying potential drugs targeting the gene DOCK8.

This study found that MEGA PROTAC improved the prediction of ternary structures with higher maximum DockQ scores compared to the BOTCP method in 16 out of 22 test cases.

This system overview describes the UTokyo Repository's role in storing and providing online access to digital resources from the University of Tokyo, reporting no new empirical findings or research results.

This study found that reduced cytokinin levels allow plants to adapt to low potassium conditions by enhancing root hair growth, reactive oxygen species accumulation, and expression of a key potassium transporter gene.

This article proposes an updated naming system for keratin-associated proteins and genes, aiming to improve data storage and retrieval by including species information and genetic variation.

In this study, topical inhibition of casein kinase 1 in mice was found to enhance melanocyte precursor migration and eumelanin production, suggesting potential applications for treating vitiligo and graying hair through KitL/c-Kit signaling pathway activation.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

In this study, researchers formulated a nanosuspension of kenikir leaf extract that meets physical criteria and exhibits cytotoxic activity against MCF-7 breast cancer cells.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

The study found that the combined administration of regulatory T cells and rapamycin improved outcomes in an experimental model of chronic graft-versus-host disease.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

In this study, researchers developed a new method called Enriched-GF, which enhances growth factor recovery from platelet concentrates through a combination of glass bead activation, freeze-thaw cycling, and calcium stimulation, outperforming conventional methods by providing higher and more consistent yields for regenerative medicine applications.

This study reported that ritlecitinib effectively improved hair regrowth in JAK inhibitor-naïve adolescent patients with severe alopecia areata, achieving significant reductions in SALT scores within 24 weeks, but was less effective for patients who had previously been treated with baricitinib.